Compare Adaptive Biotechnologies Corp (ADPT) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Grab Holdings Ltd. — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Grab Holdings Ltd. trades at $3.74 (market cap $14.97B). The key difference: Grab Holdings Ltd. is far larger — about 3.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| ADPT | GRAB | |
|---|---|---|
Market Cap | $4.05B | $14.97B |
Sector | Health | Technology |
52-Week High | $25.45 | $6.45 |
52-Week Low | $12.30 | $3.27 |
Enterprise Value | $4.12B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
GRAB trades at $3.66, down 0.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance, supported by growth in on-demand and financial services segments. Analyst sentiment is overwhelmingly positive, with 91.67% recommending Buy.
Outlook remains favorable due to sustained revenue growth and margin expansion, but risks include high valuation multiples and insider selling. The stock offers upside to the average price target of $5.86, though volatility from competitive pressures and macroeconomic headwinds warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
